HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Susman
Edward
E
edsusman@bellsouth.net
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D002626:Chemistry, Pharmaceutical / Q000639:trends; D002986:Clinical Trials as Topic; D003226:Congresses as Topic / Q000458:organization & administration*; D000069454:Darunavir; D015507:Drugs, Investigational / Q000627:therapeutic use; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D015497:HIV-1 / Q000187:drug effects / Q000472:pathogenicity*; D006801:Humans; D009570:Nitriles / Q000737:chemistry / Q000627:therapeutic use; D063065:Organophosphonates / Q000627:therapeutic use; D010446:Peptide Fragments / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D019713:Receptors, CCR5 / Q000187:drug effects; D018894:Reverse Transcriptase Inhibitors / Q000737:chemistry / Q000627:therapeutic use; D000068696:Rilpivirine; D012958:Societies, Scientific / Q000458:organization & administration*; D013449:Sulfonamides / Q000737:chemistry / Q000627:therapeutic use; D000068698:Tenofovir; D016047:Zalcitabine / Q000031:analogs & derivatives / Q000737:chemistry / Q000627:therapeutic use
D015507:Drugs, Investigational; D015700:HIV Envelope Protein gp41; D009570:Nitriles; D063065:Organophosphonates; D010446:Peptide Fragments; D011743:Pyrimidines; D019713:Receptors, CCR5; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000077560:Enfuvirtide; D016047:Zalcitabine; D000068698:Tenofovir; D000068696:Rilpivirine; D000225:Adenine; C099405:dexelvucitabine; D000069454:Darunavir